drugset / Trial / NCT01592617

Summary

The investigators identified three cancer-testis antigens, as targets for cancer vaccination against lung cancer. In this clinical study, the investigators examine using a combination of three peptides from these three antigens (S-488410) the safety, immunogenicity, and antitumor effect of vaccine treatment for advanced non-small cell lung cancer patients.

Timeline

Start
2012-05
Primary completion
2015-08
Completion
2015-09

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject S-488410 Unknown 1 mg Subcutaneous